WHO ICTRP trial
Phase III clinical study of emicizumab given every 4 weeks (Q4W) in patients…
JPRN-jRCT2080223336 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080223336 |
|---|---|
| Public title | Phase III clinical study of emicizumab given every 4 weeks (Q4W) in patients with hemophilia A |
| Scientific title | A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS (Q4W) IN PATIENTS WITH HEMOPHILIA A |
| Primary sponsor | CHUGAI PHARMACEUTICAL CO., LTD. |
| Secondary sponsors | F. Hoffmann-La Roche Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Japan;North America;Europe |
| Conditions | Hemophilia A |
| Interventions | investigational material(s) Generic name etc : Emicizumab (ACE910, RO5534262) INN of investigational material : emicizumab Therapeutic category code : 634 Human blood preparations Dosage and Administration for Investigational material… |
| Registration date | Sep 30, 2016 |
| Target size | 48 |
| Secondary IDs | NCT03020160;JapicCTI-163391 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: